# EDGAR Filing Document

**Accession Number:** 0001845337
**File Stem:** 0001193125-25-134103
**Filing Date:** 2025-6
**Character Count:** 5710
**Document Hash:** 4eb30cefa63ca65c3d1d7765495b60e5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-134103.hdr.sgml**: 20250603

**ACCESSION NUMBER**: 0001193125-25-134103

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20250602

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20250603

**DATE AS OF CHANGE**: 20250603

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Day One Biopharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001845337
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 832415215
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40431
- **FILM NUMBER:** 251019232

**BUSINESS ADDRESS:**
- **STREET 1:** 2000 SIERRA POINT PARKWAY, SUITE 501
- **CITY:** BRISBANE
- **STATE:** CA
- **ZIP:** 94005
- **BUSINESS PHONE:** 650 484-0899

**MAIL ADDRESS:**
- **STREET 1:** 2000 SIERRA POINT PARKWAY, SUITE 501
- **CITY:** BRISBANE
- **STATE:** CA
- **ZIP:** 94005

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Day One Biopharmaceuticals Holding Co LLC
- **DATE OF NAME CHANGE:** 20210209

?xml version='1.0' encoding='ASCII'? 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### WASHINGTON, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): (June 2, 2025)

## DAY ONE BIOPHARMACEUTICALS, INC.

#### (Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-40431** | **83-2415215** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission**<br> **File Number)** | **(IRS Employer**<br> **Identification No.)** |

---

#### 1800 Sierra Point Parkway, Suite 200

#### Brisbane, California

#### (Address of principal executive offices)

#### 94005

#### (Zip Code)

#### Registrant's telephone number, including area code: (650) 484-0899

#### N/A

#### (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br> **Symbol(s)** | **Name of each exchange**<br> **on which registered** |
| Common Stock, par value $0.0001 per share | DAWN | Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 5.07.** | **Submission of Matters to a Vote of Security Holders.**  |

---

On June 2, 2025, Day One Biopharmaceuticals, Inc. (the "Company") held its 2025 Annual Meeting of Stockholders and the Company's stockholders voted on and approved the following proposals:

1. The election of two Class I Directors, Natalie Holles and Garry Nicholson, M.B.A., each to serve a three-year term, which will expire at the 2028 Annual Meeting of Stockholders and until such time as their respective successors have been duly elected and qualified or until such director's earlier resignation or removal. The vote tally was as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Nominees** | **Shares For** | **Shares For** | **Shares Withheld** | **Shares Withheld** | **Broker Non-Votes** | **Broker Non-Votes** |
|  Natalie Holles |  | 81975302 |  | 1357027 |  | 6470934 |
|  Garry Nicholson, M.B.A. |  | 65553238 |  | 17779091 |  | 6470934 |

---

2. The ratification of appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025. The vote tally was as follows:

---

| | | |
|:---|:---|:---|
| **Shares For** | **Shares Against** | **Shares Abstaining** |
| 89705033 | 74951 | 23279 |

---

3. The approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers. The vote tally was as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Shares For** | **Shares Against** | **Shares Abstaining** | **Broker Non-Votes** |
| 82385592 | 879957 | 66780 | 6470934 |

---

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  |  | **DAY ONE BIOPHARMACEUTICALS, INC.** |
| Date: June 3, 2025 | By: | /s/ Charles N. York II, M.B.A. |
|  |  | Charles N. York II, M.B.A. |
|  |  | Chief Operating Officer and Chief Financial Officer |

---